trial of safflower-produced insulin in the United Kingdom in the
fourth quarter of 2008.
- Continuation of business development activities toward an insulin
In 2007, SemBioSys successfully achieved commercial levels of both Apo
AI and Apo AI(Milano) accumulation in safflower. With positive results
demonstrating safflower-produced Apo AI(Milano) increased cholesterol
mobilization in animals earlier this year, SemBioSys is continuing testing
in animals to establish that safflower-produced Apo AI(Milano) is
equivalent to microbial-produced Apo AI(Milano) with respect to
plaque-remodeling and plaque regression. The upcoming milestone events
- Completion of in vivo efficacy studies of plaque remodeling with
safflower-produced Apo AI(Milano) followed by studies of plaque
regression using a mouse model.
- Continuation of the formal partnering process for safflower-produced
Apo AI(Milano). The Company has already initiated confidential
discussions with several potential large pharmaceutical partners.
In addition to its pharmaceutical milestones, SemBioSys also expects to collect milestone payments from Arcadia Biosciences, Inc., upon their successful commercial scale-up and market launch of High GLA Safflower Oil in late 2008 or early 2009.
Meanwhile, Botaneco is also advancing the development of its personal care ingredient products with the expansion of the commercial distribution of Hydresia(TM) and Hydresia(TM) G2. With the completion of the recent funding transaction with Avrio, along with the previously committed $2.4 million from AVAC Ltd., SemBioSys expects Botaneco to be self-financing moving forward.
"The progress we have made with our two lead pharmaceutical programs,
insulin and Apo AI(Milano), over the past few months has transformed
SemBioSys. We are now poised to have insulin enter the cli
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved